Chimeric Antibody Imaging for Amyloid Deposit Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyloidosis, particularly primary amyloidosis, are ineffective in removing existing amyloid deposits and often initiated too late due to asymptomatic deposition, leading to poor prognosis and multi-organ dysfunction.
Innovation Solution
Development of humanized or chimeric antibodies specifically binding to amyloid deposits, linked with a detectable molecule for diagnostic imaging, allowing for detection, localization, and quantification of amyloid deposits, and determining appropriate therapeutic dosages based on affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional chemotherapy is used to treat amyloidosis, then the production of amyloidogenic precursor light chains is reduced, but existing amyloid deposits persist and mortality remains high
Solution Approach 1:
The treatment approach is segmented into two distinct functions: (1) chemotherapy to stop production of new amyloidogenic precursors, and (2) targeted antibody therapy to remove existing deposits. The patent applies segmentation by using different therapeutic agents for each function rather than relying on a single treatment modality.
Solution Approach 2:
The patent introduces targeted antibodies (such as 11-1F4) as intermediary agents that specifically bind to amyloid deposits. These antibodies act as mediators between the immune system and the insoluble amyloid fibrils, enabling selective removal of deposits without affecting normal tissues or stopping new production directly.
2Loss of time
If treatment is initiated based on symptomatic presentation, then conventional therapy can be administered, but treatment is often started too late after significant deposition has already occurred
Solution Approach 1:
The patent enables preliminary detection and monitoring of amyloid deposits before symptoms manifest. By using targeted antibodies with detectable labels for imaging, clinicians can identify deposits in their early stages and initiate treatment proactively rather than reactively after symptom onset.
Solution Approach 2:
The patent implements a feedback mechanism through imaging techniques that allow continuous monitoring of amyloid deposit burden. This feedback loop enables clinicians to assess treatment effectiveness in real-time and adjust therapy accordingly, ensuring treatment is maintained until deposits are adequately reduced.
3Device complexity
If uniform therapy is administered to all patients, then treatment protocol is simplified, but personalized dosing based on individual amyloid burden cannot be achieved
Solution Approach 1:
The patent transforms the static, uniform treatment approach into a dynamic, adaptive protocol. By combining initial imaging to assess amyloid burden with subsequent tailored dosing decisions, the treatment protocol becomes flexible and responsive to each patient's specific condition rather than following a rigid one-size-fits-all approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection and monitoring of amyloid deposits, facilitating targeted therapy and potentially improving treatment outcomes by allowing for personalized dosing based on patient-specific affinity.
Implementation Method 1
humanized or chimeric antibodies specifically binding to amyloid deposits
Data Source
AI summary
Methods and diagnostic compositions for detection of amyloid deposits using a chimeric (e.g., mouse-human) antibody or antigen-binding fragment thereof linked to a detectable label are disclosed.